According to the company, the EkoSonic ES design features include an advanced control unit with an easier, more intuitive user interface, making set up and operation simple. EkoSonic ES is also compatible with a new line of endovascular devices, EkoSonic Mach 4 endovascular device.
EkoSonic ES is said to be the only endovascular system that can deliver microsonic energy and thrombolytic drugs simultaneously, providing a safer, faster and more complete way to remove clots by accelerating dissolution. The EkoSonic ES recently received the FDA clearance.
Robert Hubert, Ekos president and CEO, said: “Unlike mechanical devices, EKOS technology does not fracture the thrombus or damage red blood cells. Faster clot dissolution means a lower lytic drug dosage, resulting in fewer complications. Physicians can treat patients in less time, with even greater clinical confidence.”